Cyclic platelet and leukocyte count oscillation in chronic myelocytic leukemia regulated by the negative feedback of transforming growth factor β

International Journal of Hematology

Volumn 77, Issue 1, 2003, Pages 71-74

  Hirayama, Yasuo ^a   Sakamaki, Sumio ^a   Tsuji, Yasushi ^a   Matsunaga, Takuya ^b   Niitsu, Yoshiro ^b  

^a Higashi Sapporo Hospital   (Japan)

^b SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CML; TGF ; TPO

Indexed keywords

ALPHA INTERFERON; HYDROXYUREA; RANIMUSTINE; TRANQUILIZER; MONOCLONAL ANTIBODY; TRANSFORMING GROWTH FACTOR BETA;

ADULT; ARTICLE; CASE REPORT; CHRONIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; DEPRESSION; DISEASE COURSE; FATIGUE; FEMALE; HEADACHE; HEMATOPOIESIS; HUMAN; LEUKOCYTE COUNT; MALAISE; MEGAKARYOPOIESIS; NEGATIVE FEEDBACK; OSCILLATION; RETICULOCYTE COUNT; THROMBOCYTE COUNT; TREATMENT OUTCOME; BLOOD; BLOOD CELL; CYTOLOGY; DRUG EFFECT; FEEDBACK SYSTEM; IMMUNOLOGY; MIDDLE AGED; PERIODICITY;

ANTIBODIES, MONOCLONAL; BLOOD CELLS; FEEDBACK, BIOCHEMICAL; FEMALE; HEMATOPOIESIS; HUMANS; LEUKEMIA, MYELOID, CHRONIC; LEUKOCYTE COUNT; MIDDLE AGED; PERIODICITY; PLATELET COUNT; RETICULOCYTE COUNT; TRANSFORMING GROWTH FACTOR BETA;

EID: 0037974829     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02982605     Document Type: Article

References (11)

1. Kennedy BJ. Cyclic leukocyte oscillations in chronic myelogenous leukemia during hydroxyurea therapy. Blood. 1970;35:751-760.
2. Gatti RA, Robinson WA, Deinard AS, et al. Cyclic leukocytosis in chronic myelogenous leukemia: new perspectives on pathogenesis and therapy. Blood. 1973;41:771-782.
3. Morley AA, Baikie AG, Galton DA. Cyclic leukocytosis as evidence for retention of normal homeostatic control in chronic granulocytic leukemia. Lancet. 1967;2:1320-1323.
4. Vodopick H, Rupp EM, Edwards L, Goswitz FA, Beauchamp JJ. Spontaneous cyclic leukocytosis and thrombocytosis in chronic granulocytic leukemia. N Engl J Med. 1972;286:284-290.
5. Sakamaki S, Hirayama Y, Matsunaga T, et al. Transforming growth factor-β1 (TGF-β1) induces thrombopoietin from bone marrow stromal cells, which stimulates the expression of TGF-β receptor on megakaryocytes and, in turn, renders them susceptible to suppression by TGF-β itself with high specificity. Blood. 1999;94:1961-1970.
6. Hirayama Y, Sakamaki S, Matsunaga T, et al. Concentrations of thrombopoietin in bone marrow in normal subjects and in patients with idiopathic thrombocytopenic purpura, aplastic anemia, and essential thrombocythemia correlate with its mRNA expression of bone marrow stromal cells. Blood. 1998;92:46-52.
7. Hirayama Y, Kohgo Y, Matsunaga T, Ohi S, Sakamaki S, Niitsu Y. Cytokine mRNA expression of bone marrow stromal cells from patients with aplastic anaemia and myelodysplastic sryndrome. Brit J Haematol. 1993;85:676-683.
8. Ishibashi T, Miller SL, Burstein SA. Type β transforming growth factor is a potent inhibitor of murine megakaryocytopoiesis in vitro. Blood. 1987;69:1737-1741.
9. Cashman JD, Eaves CJ, Sarris AH, Eaves AC. MCP-1, not MIP-1α, is the endogeneous chemokine that cooperates with TGF-β inhibit the cycling of primitive normal but not leukemic (CML) progenitors in long-term human marrow cultures. Blood. 1998;92:2338-2344.
10. Carlino JA, Higley HR, Creson JR, Avis PD, Ogawa Y, Ellingsworth LR. Transforming growth factor beta systemically modulates granuloid, erythroid, lymphoid, and thrombocytic cells in mice. Exp Hematol. 1992;20:943-950.
11. Letterio JJ, Geiser AG, Kulkarni AB, et al. Autoimmunity associated with TGF-β1-deficiency in mice is dependent on MHC class II antigen expression. J Clin Invest. 1996;98:2109-2119.